Successful Treatment of Refractory Bleeding After Bridging from Acute to Chronic Left Ventricular Assist Device Support with Recombinant Activated Factor VII

Publisher Website
Google Scholar
Abstract
Cardiac surgery often is associated with a significant disruption of the coagulation system, particularly in high risk patients such as those undergoing placement of ventricular assist devices. This type of severe coagulopathy can lead to life threatening bleeding that can require massive transfusions to restore hemostasis. Recently, recombinant activated factor VII (rFVIIa) has been +used as an alternative to massive transfusion for the treatment of refractory bleeding in several patient populations, including cardiac surgery patients. In the case reported here, the patient’s risk was compounded by multiple operations in a short period of time and circulatory collapse that was initially managed with a short-term left ventricular assist device. After multiple failed attempts at weaning the patient from circulatory assistance, he was taken back to the operating room for conversion to a chronic, implantable device. This procedure was complicated by a severe coagulopathy secondary to a myriad of factors commonly encountered after the use of cardiopulmonary bypass. The administration of rFVIIa resulted in a rapid cessation of bleeding without thrombotic complications. This is the first case reported involving an acute to chronic bridge patient. Despite the anecdotal success of rFVIIa, further clinical research is needed to establish both the safety and economic feasibility of this agent.

This publication has 13 references indexed in Scilit: